(2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
(2000). A novel use for the comet assay: detection of topoisomerase II inhibitors.
(2006). A tandem of SH3-like domains participates in RNA binding in KIN17, a human protein activated in response to genotoxics.
(2005). Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.
(2007). American Society of Clinical Oncology
(2009). Breast cancer metastasis: challenges and opportunities.
(2010). Cancer statistics,
(2004). Cell-cycle checkpoints and cancer.
(2008). Dicer, Drosha, and outcomes in patients with ovarian cancer.
(2007). DNA damage signalling guards against activated oncogenes and tumour progression.
(2008). DNA repair pathways as targets for cancer therapy.
(2010). Drug discovery and mutant p53.
(2008). Effect of Terminalia arjuna extract on adriamycin-induced DNA damage.
(2008). EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer.
(2008). EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy.
(1997). Enhanced expression of the Kin17 protein immediately after low doses of ionizing radiation.
(1999). Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 39-kinase and phospholipase C-dependent mechanism.
(2009). Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target.
(2003). Global genome repair is required to activate KIN17, a UVC-responsive gene involved in DNA replication.
(2011). Hallmarks of cancer: the next generation.
(2002). Human kin17 protein directly interacts with the simian virus 40 large T antigen and inhibits DNA replication.
(2010). Impact of 1.8-GHz radiofrequency radiation (RFR) on DNA damage and repair induced by doxorubicin in human B-cell lymphoblastoid cells.
(2002). Ionizing radiation triggers chromatin-bound kin17 complex formation in human cells.
(2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
(2004). KIN17 encodes an RNA-binding protein and is expressed during mouse spermatogenesis.
(1994). KIN17, a mouse nuclear protein, binds to bent DNA fragments that are found at illegitimate recombination junctions in mammalian cells. Mol Gen Genet 244: 435–438. 6 . M i c c o l iL ,F r o u i nI ,N o v a cO ,D iP a o l aD ,H a r p e rF ,e ta l
(2010). Lluch A
(2000). Molecular cloning and characterization of the human KIN17 cDNA encoding a component of the UVC response that is conserved among metazoans.
(2007). Molecularly targeted therapeutics for breast cancer.
(2010). PCB-153 exposure coordinates cell cycle progression and cellular metabolism in human mammary epithelial cells.
(2004). Relevance of breast cancer cell lines as models for breast tumours: an update.
(2007). Rubagotti A
(2004). The activities of cyclin D1 that drive tumorigenesis.
(1998). The nuclear concentration of kin17, a mouse protein that binds to curved DNA, increases during cell proliferation and after UV irradiation.
(2007). TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
(2006). Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
(2010). Triple-negative breast cancer: disease entity or title of convenience?